Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.

Hye-Lin KimGi-Ae KimJae-A ParkHye-Rim KangEui-Kyung LeeYoung Suk Lim

Published in: Gut (2020)

Starting antiviral therapy in IT phase is cost-effective compared with delaying the treatment until the active hepatitis phase in CHB patients, especially with increasing HCC risk, decreasing drug costs and consideration of productivity loss.

Keyphrases

end stage renal disease
ejection fraction
climate change
emergency department
prognostic factors
mesenchymal stem cells
peritoneal dialysis
cell therapy
replacement therapy
adverse drug
drug induced